Low business R&D a major threat to the European knowledge-based economy

European Commission presents a new publication on Europe's position in research and innovation. The "Key figures 2007 on Science, Technology and Innovation" shows that R&D intensity (R&D expenditure as % of GDP) in Europe has stagnated since the mid-nineties, while major competitors such as Japan, China or South Korea have been able to increase substantially their R&D effort, shaping a world where knowledge is more evenly distributed than ever before. Moreover, the R&D investment deficit against the US has remained constant over recent years. In particular, the low level of business R&D in the EU remains worrying. Key Figures 2007 shows that differences in the industrial structure of the EU compared to countries such as the US are the main cause for this low level of business R&D, with the EU having a smaller high-tech industrial sector, which usually has much higher levels of R&D spending. The new actions taken in Europe since 2005 in the context of the revised Lisbon Strategy need to be implemented if Europe is to successfully face this challenge.

"Knowledge is a key component of competitiveness" said European Science and Research Commissioner Janez Potočnik. "If our businesses are to be at the leading edge in the future, they need to invest in knowledge now. And governments need to put in place the appropriate measures to help them do so."

Since the last Key Figures in 2005, policy-makers have launched new initiatives at both EU and Member State level in order to boost the "Europe of Knowledge": The ambitious Seventh Framework Programme (FP7) has been adopted and is now underway with a substantially higher budget than its predecessor, FP6. Member States have made new and far-reaching commitments within the framework of the renewed Lisbon strategy by setting future R&D intensity targets. The recently published ERA Green Paper has launched a wide-ranging debate on the future orientations of the European Research Area (ERA).

Key Figures 2007 presents data and statistics on science, technology and innovation up to 2005, thus predating these recent initiatives and renewed commitments. It shows however that these recent policy developments are now more than ever needed, for at least five reasons:

  • The EU is part of a globalised world where knowledge is more evenly distributed than ever before. High competition on this level requires the EU to adapt and make the ERA more attractive to the rest of the world. The Key Figures 2007 show that countries like China already act as strong competitors in the globalised knowledge-based economy.
  • The report shows that EU R&D intensity has stagnated since the mid-nineties. In 2005, only 1.84% of GDP was spent on R&D in EU-27 and it still remains at a lower level than in the US, Japan or South Korea. Also new emerging economies such as China are rapidly catching-up. If current trends last, China will have caught up with the EU by 2009 in terms of R&D intensity. However, high R&D-intensive EU Member States such as Austria, Germany, Finland and Denmark show that it is possible to maintain and increase R&D intensity above 2% and even 3% of GDP.
  • Over 85% of the R&D intensity gap between the EU and its main competitors is caused by differences in business sector R&D financing. The low level of private R&D expenditure in Europe in comparison with the US is mostly due to differences in industrial structure and to the smaller size of the high-tech industry in the EU.
  • Regarding research excellence, although the EU is the world's largest producer of scientific knowledge, the impact of European science is lower than that of the US. Europe lags behind the US in all scientific disciplines in terms of citation impact scores and highly-cited publications. Also, EU universities are very much underrepresented at the top of a ranking based on bibliometric indicators of the world's largest universities. In addition, the linkage between technology (patented inventions) and the science base is much weaker in the EU than in the US. Europe has a difficulty in breaking through in new high-tech industries.
  • Even though private sector funds are a notable part of R&D, the public sector still has a major role to play. Public R&D funding in the EU must be sustained in order for private R&D activities to develop further and grow on a solid science base. The Key Figures 2007 reveal that high R&D intensity can be achieved when high contributions from the private sector go hand in hand with high levels of public funding. For those economies that are catching up, government funding of R&D is critical for creating and developing S&T capabilities.
For further information, please visit:
http://ec.europa.eu/invest-in-research/monitoring/statistical01_en.htm

Most Popular Now

Philips Foundation 2024 Annual Report: E…

Marking its tenth anniversary, Philips Foundation released its 2024 Annual Report, highlighting a year in which the Philips Foundation helped provide access to quality healthcare for 46.5 million people around...

New AI Transforms Radiology with Speed, …

A first-of-its-kind generative AI system, developed in-house at Northwestern Medicine, is revolutionizing radiology - boosting productivity, identifying life-threatening conditions in milliseconds and offering a breakthrough solution to the global radiologist...

Scientists Argue for More FDA Oversight …

An agile, transparent, and ethics-driven oversight system is needed for the U.S. Food and Drug Administration (FDA) to balance innovation with patient safety when it comes to artificial intelligence-driven medical...

New Research Finds Specific Learning Str…

If data used to train artificial intelligence models for medical applications, such as hospitals across the Greater Toronto Area, differs from the real-world data, it could lead to patient harm...

Giving Doctors an AI-Powered Head Start …

Detection of melanoma and a range of other skin diseases will be faster and more accurate with a new artificial intelligence (AI) powered tool that analyses multiple imaging types simultaneously...

AI Agents for Oncology

Clinical decision-making in oncology is challenging and requires the analysis of various data types - from medical imaging and genetic information to patient records and treatment guidelines. To effectively support...

Patients say "Yes..ish" to the…

As artificial intelligence (AI) continues to be integrated in healthcare, a new multinational study involving Aarhus University sheds light on how dental patients really feel about its growing role in...

Brains vs. Bytes: Study Compares Diagnos…

A University of Maine study compared how well artificial intelligence (AI) models and human clinicians handled complex or sensitive medical cases. The study published in the Journal of Health Organization...

'AI Scientist' Suggests Combin…

An 'AI scientist', working in collaboration with human scientists, has found that combinations of cheap and safe drugs - used to treat conditions such as high cholesterol and alcohol dependence...

Start-ups in the Spotlight at MEDICA 202…

17 - 20 November 2025, Düsseldorf, Germany. MEDICA, the leading international trade fair and platform for healthcare innovations, will once again confirm its position as the world's number one hotspot for...